Upstream Bio (UPB) Liabilities and Shareholders Equity (2023 - 2026)

Upstream Bio's Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $318.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 30.28% year-over-year to $318.1 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 26.73% YoY), while the FY2025 annual figure was $353.8 million, down 26.56% from the prior year.
• Liabilities and Shareholders Equity was $318.1 million for Q1 2026 at Upstream Bio, down from $353.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $481.7 million in Q4 2024 to a low of $117.2 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $346.4 million across 4 years, with a median of $372.5 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity jumped 311.03% in 2024, then sank 30.28% in 2026.
• A 4-year view of Liabilities and Shareholders Equity shows it stood at $117.2 million in 2023, then jumped by 311.03% to $481.7 million in 2024, then decreased by 26.56% to $353.8 million in 2025, then declined by 10.1% to $318.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $318.1 million (Q1 2026), $353.8 million (Q4 2025), and $391.2 million (Q3 2025), per Business Quant data.